Subcellular trafficking of proteolipid protein (PLP/DM20) and novel mechanisms of ER retention in Pelizaeus-Merzbacher disease

Missense mutations that predict the misfolding of membrane proteins have been associated with a number of neurogenetic diseases. However, it is not known how apparently minor changes in the amino acid sequence of an extracellular loop or a transmembrane domain lead to complete ER retention with complex loss- and gain-of-function effects. I have chosen PLP/DM20, a highly conserved and abundant tetraspan myelin protein, associated with Pelizaeus-Merzbacher disease (PMD), as a model system. By expressing wildtype and mutant PLP isoforms in glial cells, surprising molecular properties became apparent, including the ability to self-assemble from two truncated PLP polypeptides, and to form conformation sensitive epitope that become masked as the protein matures in the ER. With respect to human disease, it was possible to identify a novel molecular mechanism by which missense mutations cause ER retention of misfolded PLP. Unexpectedly, pairs of cysteines within an extracellular loop of PLP/DM20 play a critical role. Multiple disease-causing mutations require the presence of cysteines such that misfolded PLP/DM20 is efficiently retained in the ER. Replacing cysteines by serine completely prevents ER retention and restores normal trafficking of mutant PLP/DM20. This demonstrates a novel pathological mechanism by which missense mutations greatly reduce the efficiency of intramolecular disulfide bridging. When exposed by misfolding to the ER lumen, unpaired cysteines engage in alternative oxidations that lead to abnormal intermolecular crosslinks. Since extracellular cysteines are a feature of many membrane proteins, this novel pathomechanism is likely to contribute to a diverse group of genetic diseases. To monitor the expression and subcellular trafficking of PLP in vivo, a transgenic knock-in mouse in being generated that will express a PLP-EGFP fusion protein under control of the endogenous promoter. In an attempt to develop a cure for Pelizaeus-Merzbacher disease (PMD), we treated a genuine animal model (rumpshaker mice) with Turmeric. The active constituent of this herbal drug (Curcumin) is a non-toxic Ca2+ adenosine triphosphatase pump inhibitor, and known to release membrane proteins from ER retention. In a pilot experiment, we extended the lifespan of rumpshaker mice from 20 to 60 days. These promising data suggest that a therapeutic strategy should be developed for PMD, using turmeric and our in vitro and in vivo models

Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites

During vertebrate brain development, axons are enwrapped by myelin, an insulating membrane produced by oligodendrocytes. Neuron-derived signaling molecules are temporally and spatially required to coordinate oligodendrocyte differentiation. In this study, we show that neurons regulate myelin membrane trafficking in oligodendrocytes. In the absence of neurons, the major myelin membrane protein, the proteolipid protein (PLP), is internalized and stored in late endosomes/lysosomes (LEs/Ls) by a cholesterol-dependent and clathrin-independent endocytosis pathway that requires actin and the RhoA guanosine triphosphatase. Upon maturation, the rate of endocytosis is reduced, and a cAMP-dependent neuronal signal triggers the transport of PLP from LEs/Ls to the plasma membrane. These findings reveal a fundamental and novel role of LEs/Ls in oligodendrocytes: to store and release PLP in a regulated fashion. The release of myelin membrane from LEs/Ls by neuronal signals may represent a mechanism to control myelin membrane growth

Functional Studies of MLC1 Mutations in Chinese Patients with Megalencephalic Leukoencephalopathy with Subcortical Cysts

Megalencephalic leukoencephalopathy with subcortical cysts (MLC, MIM # 604004) is an autosomal recessive inherited disease mostly resulting from MLC1 mutations. In this study, we finished the functional analysis of MLC1 mutations identified recently in Chinese patients, including five newly described missense mutations (R22Q, A32V, G73E, A275T, Y278H), one known nonsense mutation (Y198X), and two known missense mutations (S69L, T118M). We found MLC1 wt was localized to the cell periphery, whereas mutant R22Q, A32V, G73E, S69L and T118M were trapped in the lumen of endoplasmic reticulum (ER) when we transfected the wild-type and mutant MLC1 in U373MG cells. Compared to wild type, the mutant G73E, T118M, Y198X and A275T transcript decreased and all mutants except R22Q had lower protein expression in transfected U373MG cells. Therefore, we propose that all these eight MLC1 mutations had functional effect either on thei

Oligonucleotide primers used to generate <i>MLC1</i> mutants.

<p>Oligonucleotide primers used to generate <i>MLC1</i> mutants.</p

Some MLC1 mutants were retained intracellularly and co-localized with an ER marker.

<p>Confocal images of transfected U373MG cells expressing various MLC1 mutants immunostained with anti-HA antibody (green) and calnexin (red) were shown (magnified in Inset). Mutant MLC1 staining mostly overlapped with calnexin for A32V. Y198X showed minimal co-staining with calnexin and was expressed like MLC1<i>^wt</i>. The bar was 30 µm (Other data not shown).</p

Protein expressions of MLC1<i>^wt</i> and the mutants.

<p>Calnexin was an internal control and MLC1 proteins were tagged by HA. Cont was the control without transfection.</p

Statistics for protein expressions.

<p>We defined WT as 1. Except for R22Q, all other mutations resulted in significant downregulation in mutant MLC1 protein levels (n = 4). The statistics of these data was compiled by T test in Prism 5 (*** <i>P<0.001</i>, ** <i>P<0.01</i>, * <i>P<0.05</i>, compared with WT).</p

A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis

<div><p>Clinical trial results demonstrating that B-cell depletion substantially reduces new relapses in patients with multiple sclerosis (MS) have established that B cells play a role in the pathophysiology of MS relapses. The same treatment appears not to impact antibodies directed against the central nervous system, which underscores the contribution of antibody-independent functions of B cells to disease activity. One mechanism by which B cells are now thought to contribute to MS activity is by over-activating T cells, including through aberrant expression of B cell pro-inflammatory cytokines. However, the mechanisms underlying the observed B cell cytokine dysregulation in MS remain unknown. We hypothesized that aberrant expression of particular microRNAs might be involved in the dysregulated pro-inflammatory cytokine responses of B cells of patients with MS. Through screening candidate microRNAs in activated B cells of MS patients and matched healthy subjects, we discovered that abnormally increased secretion of lymphotoxin and tumor necrosis factor α by MS B cells is associated with abnormally increased expression of miR-132. Over-expression of miR-132 in normal B cells significantly enhanced their production of lymphotoxin and tumor necrosis factor α. The over-expression of miR-132 also suppressed the miR-132 target, sirtuin-1. We confirmed that pharmacological inhibition of sirtuin-1 in normal B cells induces exaggerated lymphotoxin and tumor necrosis factor α production, while the abnormal production of these cytokines by MS B cells can be normalized by resveratrol, a sirtuin-1 activator. These results define a novel miR-132-sirtuin-1 axis that controls pro-inflammatory cytokine secretion by human B cells, and demonstrate that a dysregulation of this axis underlies abnormal pro-inflammatory B cell cytokine responses in patients with MS.</p></div